Falsified Medicines Directive
Global Traceability and Serialisation in Pharma Report
June 29 by Pharmaceuticals & Biotechnology EditorFake pharmaceuticals have the potential to be harmful for consumption. This possibility was seen back in 2013 when the FDA alerted the industry of the existence of a counterfeit cancer medicine that w...
Making the business case for implementing serialization cost-effectively
June 11 by Nitin DahadAs part of the implementation of serialization, automation of the process will become law within 10 years. As already highlighted previously, serialization provides accountability a...
Pharmaceutical Serialisation & Traceability 2015 Report
May 31 by Pharma IQ SurveysPharma IQ would like to invite you to take part in this short industry survey. The survey will take less than 10 minutes to complete and as a thank you, all participants who complete the survey c...
Falsification and Pharmacovigilance: What Do Patients Get to See and What Should They Do with It?
March 19 by Pharmaceuticals & Biotechnology EditorAre we really ‘enabling patients to act appropriately’? The ‘Falsified medicines directive’ (2011/62/EU) and the ‘Pharmacovigilance regulation’ (No 1235/...
Top 5 Strategies for Emerging Biotechs Infographic
September 24 by Pharmaceuticals & Biotechnology EditorSmall biotech companies can run into a variety of problems when starting up. In this infographic we take a closer look at BIO's top 5 strategies for small business success. ...
Legal Flash: 8 Regulations set to impact the Pharma & Biotech Industry in 2013
April 15 by Niamh MadiganPharma IQ has put together a list of 8 regulations and guidelines that look set to impact different divisions of the biotech and pharma industry in 2013. ONE: Good Distributio...
Ensure Manufacturing Readiness: Practical Steps to Prepare for Delegated Acts
March 26 by Niamh MadiganThe Delegated Acts are due to come into force in 2017 and no company, big or small, can be in a position to sit waiting for the specific delegated acts to be released following the falsifi...
Boehringer Ingelheim's Johannes Schoen on How to Prepare for the Falsified Medicines Directive
February 18 by Pharmaceuticals & Biotechnology EditorIn this recent interview, Johannes Schoen, Supply Network Quality Management Anti-Counterfeitng, Boehringer Ingelheim speaks to Andrea Charles from Pharma IQ, following facilitating the "Anti-Counterf...
How to Deliver Cost Effective Pharmaceutical Global Artwork
May 01 by Niamh MadiganLabelling and Artwork are still the highest causes of the recall of pharmaceutical products. Andrew Love, Vice President at Pharmaceutical Advisory Services, Be4ward Ltd, and former...
Fighting Counterfeit Medicines: What's Next?
March 08 by Andrea CharlesJim Thomson, Chair, European Alliance for Safe Medicines (EAASM), joins Pharma IQ to discuss pharmaceutical counterfeiting, new EU legislation and EAASM’s recommendations. [inlinead]
2017: Preparing for the Falsified Medicines Directive
April 26 by Johannes SchoenJohannes Schoen, Supply Network Quality Management Anti-Counterfeitng, Boehringer Ingelheim speaks to Pharma IQ, following facilitating the "Anti-Counterfeiting: Falsified Medicines Directive a...
How to Deliver Cost Effective Pharmaceutical Global Artwork
April 26 by Andrew LoveLabelling and Artwork are still the highest causes of the recall of pharmaceutical products. Andrew Love, Vice President at Pharmaceutical Advisory Services, Be4ward Ltd, and former Director of G...